Delivery Order SPE2DB25D3003-SPE2DB25FPVSJ

Award Date 2/3/25
Potential Completion Date 2/25/25
Potential Value $6.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $3,203.98, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PROQUAD VIALS, a medical product, with a completion date of February 6, 2024. This award is a delivery order under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,654.33, is a delivery order for PROQUAD VIALS and has a completion date of February 24, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,654.33 delivery order contract is for the procurement of PROQUAD VIALS, a pharmaceutical product. The contract is a Firm Fixed Price agreement with a period of performance through February 26, 2025. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of PROQUAD VIALS, medical supplies valued at $7,167.50. The award, which is a Delivery Order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, has a firm fixed price and an ultimate completion date of September 6, 2022. The contract does not have a set-aside designation, indicating open...
This federal contract award, valued at $1,601.99, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of PROQUAD VIALS. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive range of medical commodities from Amerisourcebergen to support military...
This federal contract award, valued at $1,687.48, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PROQUAD VIALS, a medical product, with an ultimate completion date of January 29, 2025. The contract is a Firm Fixed Price Delivery Order and was not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,141.08 firm fixed-price delivery order is for the supply of PROQUAD VIALS, a medical product. The contract has an ultimate completion date of November 20, 2024 and was awarded on October 29, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,645.06 firm-fixed-price delivery order is for the procurement of PROQUAD VIALS, a medical supply. The contract has an ultimate completion date of January 8, 2025 and was awarded on December 16, 2024. This award is a child contract under Amerisourcebergen's $999,999,999 Indefinite Delivery...
This federal contract award, valued at $19,485.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4566619233 units of PROQUAD VIALS, a medical product, with a completion date of December 23, 2024. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award of $1,687.48 was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PROQUAD VIALS, a vaccine product, with a performance period through February 6, 2025. The award is issued as a Delivery Order under a broader Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and...
  • SPE2DB25D3003
    Indefinite Delivery Contract
  • SPE2DB25D3003-SPE2DB25FPVSJ
    Delivery Order

This federal contract award, valued at $6,405.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PROQUAD VIALS, a type of medical product, with a performance period through February 25, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award did not include any set-aside designations, indicating open competition.

Generated 5/5/25, 9:57 AM